Emerging issues in probiotic safety: 2023 perspectives

Daniel Merenstein; Bruno Pot; Gregory Leyer; Arthur C Ouwehand; Geoffrey A Preidis; Christopher A Elkins; Colin Hill; Zachery T Lewis; Andrea L Shane; Niv Zmora; Mariya I Petrova; Maria Carmen Collado; Lorenzo Morelli; Gina A Montoya; Hania Szajewska; Daniel J Tancredi; Mary Ellen Sanders

doi:10.1080/19490976.2023.2185034

Emerging issues in probiotic safety: 2023 perspectives

Daniel Merenstein, Bruno Pot, Gregory Leyer, Arthur C Ouwehand, Geoffrey A Preidis, Christopher A Elkins, Colin Hill, Zachery T Lewis, Andrea L Shane, Niv Zmora, Mariya I Petrova, Maria Carmen Collado, Lorenzo Morelli, Gina A Montoya, Hania Szajewska, Daniel J Tancredi, Mary Ellen Sanders

Research output: Contribution to journal › Article › peer-review

139 Citations (Scopus)

180 Downloads (Pure)

Abstract

Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety.

Original language	English
Article number	2185034
Number of pages <span style="color:red"p> <font size="1.5"> ✽ </span> </font>	22
Journal	Gut Microbes
Volume	15
Issue number	1
DOIs	https://doi.org/10.1080/19490976.2023.2185034
Publication status	Published - 2023

Bibliographical note

Funding Information:
ISAPP provided travel funding for non-industry-affiliated members of this expert panel. ISAPP is funded by equal contributions from member companies involved in the development, assessment, or marketing of probiotic or prebiotic products. Although ISAPP receives funds to support its activities from commercial sources, its activities and positions are set by an all-academic, volunteer board of scientists. Industry members have no control over the positions of the organization.

Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.

Keywords

Anti-Bacterial Agents/adverse effects
Gastrointestinal Microbiome
Prebiotics
Probiotics/adverse effects

Access to Document

10.1080/19490976.2023.2185034Licence: CC BY

95341003Final published version, 2.02 MBLicence: CC BY

Cite this

Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., Petrova, M. I., Collado, M. C., Morelli, L., Montoya, G. A., Szajewska, H., Tancredi, D. J., & Sanders, M. E. (2023). Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes, 15(1), [2185034]. https://doi.org/10.1080/19490976.2023.2185034

Merenstein, Daniel ; Pot, Bruno ; Leyer, Gregory ; Ouwehand, Arthur C ; Preidis, Geoffrey A ; Elkins, Christopher A ; Hill, Colin ; Lewis, Zachery T ; Shane, Andrea L ; Zmora, Niv ; Petrova, Mariya I ; Collado, Maria Carmen ; Morelli, Lorenzo ; Montoya, Gina A ; Szajewska, Hania ; Tancredi, Daniel J ; Sanders, Mary Ellen. / Emerging issues in probiotic safety : 2023 perspectives. In: Gut Microbes. 2023 ; Vol. 15, No. 1.

@article{6bc779ffa79d48918466cc4eefdbf714,

title = "Emerging issues in probiotic safety: 2023 perspectives",

abstract = "Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety.",

keywords = "Anti-Bacterial Agents/adverse effects, Gastrointestinal Microbiome, Prebiotics, Probiotics/adverse effects",

author = "Daniel Merenstein and Bruno Pot and Gregory Leyer and Ouwehand, {Arthur C} and Preidis, {Geoffrey A} and Elkins, {Christopher A} and Colin Hill and Lewis, {Zachery T} and Shane, {Andrea L} and Niv Zmora and Petrova, {Mariya I} and Collado, {Maria Carmen} and Lorenzo Morelli and Montoya, {Gina A} and Hania Szajewska and Tancredi, {Daniel J} and Sanders, {Mary Ellen}",

note = "Funding Information: ISAPP provided travel funding for non-industry-affiliated members of this expert panel. ISAPP is funded by equal contributions from member companies involved in the development, assessment, or marketing of probiotic or prebiotic products. Although ISAPP receives funds to support its activities from commercial sources, its activities and positions are set by an all-academic, volunteer board of scientists. Industry members have no control over the positions of the organization. Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. Copyright: Copyright 2023 Elsevier B.V., All rights reserved.",

year = "2023",

doi = "10.1080/19490976.2023.2185034",

language = "English",

volume = "15",

journal = "Gut Microbes",

issn = "1949-0976",

publisher = "Landes Bioscience",

number = "1",

}

Emerging issues in probiotic safety : 2023 perspectives. / Merenstein, Daniel; Pot, Bruno; Leyer, Gregory; Ouwehand, Arthur C; Preidis, Geoffrey A; Elkins, Christopher A; Hill, Colin; Lewis, Zachery T; Shane, Andrea L; Zmora, Niv; Petrova, Mariya I; Collado, Maria Carmen; Morelli, Lorenzo; Montoya, Gina A; Szajewska, Hania; Tancredi, Daniel J; Sanders, Mary Ellen.

In: Gut Microbes, Vol. 15, No. 1, 2185034, 2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Emerging issues in probiotic safety

T2 - 2023 perspectives

AU - Merenstein, Daniel

AU - Pot, Bruno

AU - Leyer, Gregory

AU - Ouwehand, Arthur C

AU - Preidis, Geoffrey A

AU - Elkins, Christopher A

AU - Hill, Colin

AU - Lewis, Zachery T

AU - Shane, Andrea L

AU - Zmora, Niv

AU - Petrova, Mariya I

AU - Collado, Maria Carmen

AU - Morelli, Lorenzo

AU - Montoya, Gina A

AU - Szajewska, Hania

AU - Tancredi, Daniel J

AU - Sanders, Mary Ellen

N1 - Funding Information: ISAPP provided travel funding for non-industry-affiliated members of this expert panel. ISAPP is funded by equal contributions from member companies involved in the development, assessment, or marketing of probiotic or prebiotic products. Although ISAPP receives funds to support its activities from commercial sources, its activities and positions are set by an all-academic, volunteer board of scientists. Industry members have no control over the positions of the organization. Publisher Copyright: © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. Copyright: Copyright 2023 Elsevier B.V., All rights reserved.

PY - 2023

Y1 - 2023

N2 - Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety.

AB - Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety.

KW - Anti-Bacterial Agents/adverse effects

KW - Gastrointestinal Microbiome

KW - Prebiotics

KW - Probiotics/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85150241756&partnerID=8YFLogxK

U2 - 10.1080/19490976.2023.2185034

DO - 10.1080/19490976.2023.2185034

M3 - Article

C2 - 36919522

VL - 15

JO - Gut Microbes

JF - Gut Microbes

SN - 1949-0976

IS - 1

M1 - 2185034

ER -

Emerging issues in probiotic safety: 2023 perspectives

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this